Takeda announced additional workforce reductions, starting with nearly 250 Cambridge-area employees as part of a broader cost-saving plan. A state filing stated layoffs begin in July, though some roles will be affected later in the year or in 2027. The company tied the restructuring to an expected $1.25 billion in annual savings by 2028, with possible additional cuts in other states. The actions follow Takeda’s earlier restructuring efforts tied to margin improvement targets and prior program and portfolio changes. For biotech professionals, the key signal is continued biopharma tightening: even large diversified companies are reducing headcount to fund pipeline priorities and protect margins, affecting vendor ecosystems, trial staffing, and talent movement.